Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study

S. Vitko, Z. Wlodarczyk, L. Kyllönen, Z. Czajkowski, R. Margreiter, L. Backman, F. Perner, P. Rigotti, B. Jaques, D. Abramowicz, M. Kessler, J. Sanchez-Plumed, L. Rostaing, R. S. Rodger, D. Donati, Y. Vanrenterghem

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Tacrolimus combined with mycophenolate mofetil (MMF) is an effective regimen in kidney transplantation. This study compared the efficacy of combining tacrolimus and two different dosages of sirolimus with an established tacrolimus-MMF regimen. Each day in addition to tacrolimus, 325 patients received 2 mg sirolimus (TAC-SRL2 mg), 325 patients received 0.5 mg sirolimus (TAC-SRL0.5 mg) and 327 patients 1 g MMF (TAC-MMF). The initial tacrolimus dose was 0.2 mg/kg/day. Sirolimus patients received loading doses of 6 or 1.5 mg, and daily doses of 2 or 0.5 mg thereafter. Steroid administration was identical for all groups. The incidence of biopsy-proven acute rejection was lower in the TAC-SRL2 mg group (15.7%) compared with the TAC-SRL0.5 mg (25.2%, p = 0.003) and the TAC-MMF groups (22.3%, p = 0.036). Six-month graft survival was 91.0% (TAC-SRL2 mg), 92.6% (TAC-SRL0.5 mg) and 92.4% (TAC-MMF); the respective values for patient survival were 98.1%, 97.8% and 97.9%. Thirty-four patients (10.5%), 19 patients (5.8%) and 16 patients (4.9%) in the TAC-SRL2 mg, TAC-SRL0.5 mg and TAC-MMF groups, respectively, discontinued the study because of adverse events. Hyperlipemia was reported more often in the TAC-SRL2 mg group (24.0%) compared with 19.4% (TAC-SRL0.5 mg) and 11.0% (TAC-MMF; p < 0.05). Combining 2 mg sirolimus/day with tacrolimus results in lower rates of acute rejection, but a higher incidence of adverse events.

Original languageEnglish
Pages (from-to)531-538
Number of pages8
JournalAmerican Journal of Transplantation
Volume6
Issue number3
DOIs
Publication statusPublished - Mar 2006

Keywords

  • Efficacy
  • Kidney transplantation
  • Safety
  • Sirolimus
  • Tacrolimus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Vitko, S., Wlodarczyk, Z., Kyllönen, L., Czajkowski, Z., Margreiter, R., Backman, L., Perner, F., Rigotti, P., Jaques, B., Abramowicz, D., Kessler, M., Sanchez-Plumed, J., Rostaing, L., Rodger, R. S., Donati, D., & Vanrenterghem, Y. (2006). Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. American Journal of Transplantation, 6(3), 531-538. https://doi.org/10.1111/j.1600-6143.2005.01193.x